Targeting 14-3-3θ-mediated TDP-43 pathology in amyotrophic lateral sclerosis and frontotemporal dementia mice
Yazi D Ke,Annika van Hummel,Carol Au,Gabriella Chan,Wei Siang Lee,Julia van der Hoven,Magdalena Przybyla,Yuanyuan Deng,Miheer Sabale,Nicolle Morey,Josefine Bertz,Astrid Feiten,Stefania Ippati,Claire H Stevens,Shu Yang,Amadeus Gladbach,Nikolas K Haass,Jillian J Kril,Ian P Blair,Fabien Delerue,Lars M Ittner,Yazi D. Ke,Claire H. Stevens,Nikolas K. Haass,Jillian J. Kril,Ian P. Blair,Lars M. Ittner
DOI: https://doi.org/10.1016/j.neuron.2024.01.022
IF: 16.2
2024-02-01
Neuron
Abstract:Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are characterized by cytoplasmic deposition of the nuclear TAR-binding protein 43 (TDP-43). Although cytoplasmic re-localization of TDP-43 is a key event in the pathogenesis of ALS/FTD, the underlying mechanisms remain unknown. Here, we identified a non-canonical interaction between 14-3-3θ and TDP-43, which regulates nuclear-cytoplasmic shuttling. Neuronal 14-3-3θ levels were increased in sporadic ALS and FTD with TDP-43 pathology. Pathogenic TDP-43 showed increased interaction with 14-3-3θ, resulting in cytoplasmic accumulation, insolubility, phosphorylation, and fragmentation of TDP-43, resembling pathological changes in disease. Harnessing this increased affinity of 14-3-3θ for pathogenic TDP-43, we devised a gene therapy vector targeting TDP-43 pathology, which mitigated functional deficits and neurodegeneration in different ALS/FTD mouse models expressing mutant or non-mutant TDP-43, including when already symptomatic at the time of treatment. Our study identified 14-3-3θ as a mediator of cytoplasmic TDP-43 localization with implications for ALS/FTD pathogenesis and therapy.
neurosciences